Loading condition report…
Loading condition report…
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
Evidence at a glance
Open any number to go directly to the underlying records.
The report maps directly scoped documents, study registrations, formulations and exact source-reported evidence. Efficacy, treatment and safety conclusions remain unvalidated. Every item links back to preserved source material. Study registrations and dose records describe what researchers reported or planned; they are not treatment advice or proof that an intervention works.
Condition scope
Subtype counts can overlap because one article may discuss more than one condition.
Research map
These are document-level associations. The first group has study-registration or regulatory context; neither group proves efficacy or clinical use.
Multiple-sclerosis-associated spasticity · Relapsing-remitting multiple sclerosis · Secondary progressive multiple sclerosis
registered studies · not a treatment claimMultiple-sclerosis-associated spasticity
registered studies · not a treatment claimRelapsing-remitting multiple sclerosis · Secondary progressive multiple sclerosis
Relapsing-remitting multiple sclerosis · Secondary progressive multiple sclerosis
document association · not a treatment claimMultiple-sclerosis-associated spasticity
document association · not a treatment claimMultiple-sclerosis-associated spasticity
document association · not a treatment claimHow treatment was studied
Routes and dose values below describe registered or published research. They are not prescribing instructions.
What researchers planned or recorded in trial registrations.
No exact dose descriptions were present in this frozen report snapshot.
How the intervention was described as being given in registered studies.
Open a route to see its registrations. A study may appear under more than one route.
Source-backed observations from readable publications.
Systematic review: researchers use a documented method to find, select and assess all relevant studies for a specific question.
Meta-analysis: when the studies are sufficiently comparable, their numerical results are combined statistically.
These methods can provide a broader view than one study, but their reliability still depends on the quality and similarity of the included evidence. They do not automatically prove that a treatment works.
No publication-level dosing evidence is available in this frozen snapshot.
How the research was designed
These labels describe the registered study design—not whether the treatment worked. A study can use several methods, so categories may overlap. Protocol categories are deterministic title/type matches and use a multi-label taxonomy. Filters preserve every matching tag while each registration is shown once. Registration is not a result.
Showing 12 of 43 unique registrations. 48 pattern memberships are preserved as badges; counts may overlap.
An open-label extension study in which patients with multiple sclerosis received GW-1000-02 \[named Sativex® in Canada and also named Sativex® Oromucosal Spray\] for four weeks in an open-label manner.
Open study recordA study to compare the efficacy of GW-1000-02 \[named Sativex® in Canada and also named Sativex® Oromucosal Spray\] with placebo in relieving five key symptoms of Multiple Sclerosis after six weeks of therapy.
Open study recordThis study will be conducted to evaluate the effect of multiple doses of nabiximols as adjunctive therapy compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Modified Ashworth Scale Lower Limb Muscle Tone-6 \[MAS LLMT-6\]) in participants with multiple sclerosis (MS) who have not achieved adequate relief from spasticity with other antispasticity medications.
Open study recordResearch frequency
Counts use the directly scoped, rights-cleared article snapshot. The current year is partial.
Registries
A registration describes the protocol. When posted, source-reported outcomes and safety are preserved on the local Study page.
Browse the complete filtered study catalog →
Showing 12 of 60 directly scoped registrations.
250 enrolled
Open study record20 enrolled
Open study record337 enrolled
Open study record189 enrolled
Open study record154 enrolled
Open study record36 enrolled
Open study record160 enrolled
Open study record572 enrolled
Open study record135 enrolled
Open study record279 enrolled
Open study record339 enrolled
Open study record68 enrolled
Open study recordSupporting evidence and regulatory context
Available items are locally preserved, frozen candidates. Funding and related research remain unavailable until a complete relevance-policy-v2 section is frozen; unavailable safety linkage is never presented as zero. Source metadata and safety reports are not efficacy or causality claims.
Frozen 14/09/2026 · 3,827 records · source sync still in progress
Project Narrative Cannabis is frequently used by people living with multiple sclerosis (MS), however its adverse effects are known to worsen their disease-related disability. There are currently few if any accessible interventions available to the MS patient seeking to reduce their use of cannabis, and the need for scalable, remote therapeutics to decrease distress in these individuals is more important than ever given the need for telehealth and increase of substance use disorders during the worldwide burden of COVID-19. We will target the distress component in the cycle of dependency, where cannabis use results in increased distress and in turn the increase in distress drives continued use to cope, by evaluating a novel noninvasive neuromodulation approach – remotely supervised transcranial direct current stimulation (RS-tDCS) – as tool to reduce distress and cannabis use.
Project Narrative Cannabis is frequently used by people living with multiple sclerosis (MS), however its adverse effects are known to worsen their disease-related disability. There are currently few if any accessible interventions available to the MS patient seeking to reduce their use of cannabis, and the need for scalable, remote therapeutics to decrease distress in these individuals is more important than ever given the need for telehealth and increase of substance use disorders during the worldwide burden of COVID-19. We will target the distress component in the cycle of dependency, where cannabis use results in increased distress and in turn the increase in distress drives continued use to cope, by evaluating a novel noninvasive neuromodulation approach – remotely supervised transcranial direct current stimulation (RS-tDCS) – as tool to reduce distress and cannabis use.
Unavailable. Governed relevance linkage is not ready for this frozen snapshot; no absence of records is inferred.
No matching records in this frozen snapshot.
FAERS package linkage is unavailable; zero reports must not be inferred until exact governed medicine links are ready.
Regulatory records
Registry Results
Registry-submitted primary-outcome values are shown with exact local provenance. The service does not infer efficacy, effect direction or a treatment recommendation from these unreviewed values.
The registry has not posted a Results section for these records. A protocol does not show whether the intervention worked.No registry Results section is pinned in this frozen report snapshot.
A registration describes what was planned. It does not show whether the intervention worked.
Safety
The linked evidence is source-reported and remains candidate-only. Contraindications and patient-specific guidance are not yet validated.
Latest additions
The articles, studies and medicine records shown here are fixed to one dated snapshot. Their source identifiers and links were checked, but the platform has not turned registry entries into clinical conclusions.
This condition is normalized as D009103 using Medical Subject Headings 2026.
10,202 source identifiers verified · snapshot record 32a80a606156...Dates are derived from this report's immutable package pins. A failed refresh does not replace the last good report.
Limits
Showing 12 of 3,789 frozen records. Browse the complete set →